Status: Not yet recruiting
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
This is a phase I/II trial of SHB-02-CD19, T-cell expressing an anti-CD19 Chimeric-Antigen-Receptor (CAR) in patients with CD19 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed/refractory B-cell malignancies.
Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 1-80Biological sex: AllType: InterventionalSponsor: Sheba Medical CenterUpdated: Mar 31, 2026Locations: 1
Eligibility criteria
Relapse following standard relapse protocol (2nd relapse) [+15]
Hyperleukocytosis (WBC>50,000) or rapidly progressive disease that in the judgme... [+3]